PRKAA2 and breast cancer: However, a recent clinical trial demonstrated that the AMPK-activating drug, metformin, did not significantly diminish doxorubicin-induced cardiac injury in breast cancer patients [18], suggesting activation of AMPK alone may be insufficient for cardioprotection.